Skip to content

Goodwill at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$25.96B-1.8%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$55.19B+18.7%
Danaher logo
DanaherDHR
$42.77B+2.7%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$53.73M+144%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$4.51M0.0%
TEC
Bio-TechneTECH
$977.8M+0.9%

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s goodwill?
Cytek Biosciences, Inc. (CTKB) reported goodwill of $16.69M in Q1 2026.
How has Cytek Biosciences, Inc.'s goodwill changed year-over-year?
Cytek Biosciences, Inc.'s goodwill increased by 0.1% year-over-year, from $16.68M to $16.69M.
What is the long-term trend for Cytek Biosciences, Inc.'s goodwill?
Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s goodwill has grown at a 103.7% compound annual growth rate (CAGR), from $476K to $16.7M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.